The role of C5a in the development of thrombotic glomerulonephritis in rats.
Thrombus formation is the important pathologic finding observed in glomerulonephritis induced by antiglomerular basement membrane (GBM) antibodies. Although strong deposition of C3 and membrane attack complex (MAC) is observed in this disease, the role of complement has not been fully elucidated. The aim of this work was to investigate the role of complement, especially an anaphylatoxin C5a, in a rat model of thrombotic glomerulonephritis. Rats were first pretreated with subclinical dose of lipopolysaccharide (LPS). Thrombotic glomerulonephritis was then induced by intravenous injection with rabbit antirat GBM (RbAGBM) (Group I). For the evaluation of the role of complement, the soluble complement receptor type 1 (sCR1) (Group II) or the C5a receptor antagonist peptide (C5aR-AP) (Group III) was intravenously administered 30 min before RbAGBM injection. For exploring the role of neutrophils, rats were pretreated with cyclophosphamide before induction of disease (Group IV). All rats were sacrificed at 6 h, and histological examination was performed. Rats in Group I developed severe glomerular thrombosis. Leucocyte accumulation and strong binding of C3 and MAC were observed in the glomeruli. In rats treated with sCR1 (Group II) and C5aR-AP (Group III), both leucocyte accumulation and thrombus formation in the glomeruli were significantly inhibited. C3 and MAC were negative in the glomeruli in Group II rats, while they were strongly observed in Group III. In neutrophil depleted rats (Group IV), there was also deposition of C3 and MAC in the glomeruli but thrombus formation was not observed. These findings indicated that glomerular thrombosis is dependent on the leucocytes, and mediated in part by the anaphylatoxin C5a but not MAC in the present model.
Kondo
C
C
The Third Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan.
Mizuno
M
M
Nishikawa
K
K
Yuzawa
Y
Y
Hotta
N
N
Matsuo
S
S
D000818:Animals; D015703:Antigens, CD; D002634:Chemotaxis, Leukocyte; D015936:Complement C5a / Q000378:metabolism*; D003169:Complement Inactivator Proteins; D003520:Cyclophosphamide; D005260:Female; D005921:Glomerulonephritis / Q000209:etiology*; D007678:Kidney Glomerulus / Q000098:blood supply / Q000473:pathology*; D007962:Leukocytes / Q000166:cytology; D009504:Neutrophils / Q000166:cytology; D011817:Rabbits; D051381:Rats; D044087:Receptor, Anaphylatoxin C5a; D011951:Receptors, Complement / Q000037:antagonists & inhibitors; D013927:Thrombosis / Q000209:etiology*
D015703:Antigens, CD; D003169:Complement Inactivator Proteins; D044087:Receptor, Anaphylatoxin C5a; D011951:Receptors, Complement; D015936:Complement C5a; D003520:Cyclophosphamide